Carolinas HealthCare System

Research and Clinical Trials

HIV 

Brief Description Principal Investigator
The purpose of this study is to evaluate the experimental drug elvitegravir which is one of a new class of anti-HIV medications called integrase inhibitors. The study will attempt to determine if elvitegravir is safe and effective when given in combination with the background regimen (the other antiviral medications that a patient may currently be taking or will take to participate in the study), in subjects who are failing their current regimen of HIV medications. Johnson, Marc 
A study for HIV-1 infected individuals currently taking Complera┬« with an undectable viral load. Complera will be compared to an investigational fixed dose combination (FDC) tablet containing FTC/RPV/TAF. The trial is not only measuring the effectiveness of the medication to suppress viral load, but also comparing the side effects of the two medications. Patients will be asked to follow-up for at least one year. Fixed Dose Combination tablets help to decrease the pill burden for patients. Johnson, Marc 
HIV treatment experienced study looking at those on a current regimen containing EFV/FTC/TDF FDC (Atripla) to continue treatment, versus switching to FTC/RPV/TAF FDC. Polk, Christopher 
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of the combination of etravirine 400mg with darunavir/ritonavir 800/100mg, all given once a day. In addition, this study will compare changes in cholesterol and blood sugar, along with changes in body fat, bone density, and markers of inflammation and immune function from Baseline (Day 1) to Week 48. Finally, the study will also assess the levels of these drugs in the body. Johnson, Marc 
To determine the safety and efficacy of an experimental drug, abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) fixed dose combination as a single tablet regimen compared with subjects taking their current combined antiretroviral therapy (cART) for the treatment of HIV-1 infected adults in whome the HIV-1 virus is currently suppressed. Johnson, Marc 
The purpose of this study is to determine the safety and efficacy of an experimental drug, abacavir/dolutegravir/lamivudine (ABC/DTG/3TC) fixed dose combination as a single tablet regimen compared with subjects taking their current combined antiretroviral therapy (cART) for the treatment of HIV-1 infected adults in whom the HIV-1 virus is currently suppressed Johnson, Marc 
About Carolinas HealthCare System
Who We Are
Leadership
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Foundation
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Privacy
Financial Assistance
Quality & Value Reports
Insurance
Careers
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.